close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

169.38 +1.83 (+1.09%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
News headline image
Jim Cramer Calls Axsome A 'Double Or Nothing Stock,' Says SAP Is 'Incredible' ↗
Jim Cramer discusses Torm, Trane, Sap and Axsome Therapeutics on CNBC's "Mad Money Lightning Round." 
Via Benzinga
News headline image
7 Biotech Stocks to Keep on Your Clinical Radar ↗
Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs. 
Via InvestorPlace
News headline image
Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong Future ↗
Needham initiated coverage on Axsome Therapeutics, highlighting its diverse CNS portfolio. The analyst predicts an 8-10x risk-adjusted topline growth in five years, driven by marketed drugs Auvelity... 
Via Benzinga
News headline image
Decoding 9 Analyst Evaluations For Axsome Therapeutics ↗
 
Via Benzinga
News headline image
Bull Market and Beyond: 2 Stocks Just Waiting to Soar ↗
These innovative drugmakers are hard to ignore. 
Via The Motley Fool
News headline image
Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Should You Buy This Sinking Stock on the Dip? ↗
The biotech isn't having the best year. 
Via The Motley Fool
News headline image
The 3 Best Biotech Stocks to Buy in July 2024 ↗
For investors looking for promising biotech investments should explore the best biotech stocks to watch in July 2024. 
Via InvestorPlace
News headline image
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets ↗
These three undervalued biotech stocks have begun garnering investor attention as their treatments show promise. 
Via InvestorPlace
News headline image
Why Axsome Therapeutics Stock Is Sinking Today ↗
A short-seller report is causing a sell-off of the biotech stock. 
Via The Motley Fool
News headline image
15 Analysts Assess Axsome Therapeutics: What You Need To Know ↗
 
Via Benzinga
News headline image
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Peeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insights ↗
 
Via Benzinga
News headline image
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
Data on solriamfetol featured in two oral plenary sessions 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Hello Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
3 Monster Stocks in the Making You Can Buy Right Now ↗
These stocks might not be small for too much longer. 
Via The Motley Fool
News headline image
The 3 Most Undervalued Biotech Stocks to Buy in May 2024 ↗
Three most undervalued biotech stocks to buy now will take off in the coming years and bring back continuous, hefty returns. 
Via InvestorPlace
News headline image
Prediction: These 2 Growth Stocks Could Triple By 2030 ↗
These companies have a habit of silencing the bears. 
Via The Motley Fool
News headline image
Axsome Therapeutics to Present at Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript ↗
AXSM earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
AXSM Stock Earnings: Axsome Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
AXSM stock results show that Axsome Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition ↗
Here are our top three choices for biotech stocks with blockbuster drug pipelines that could pay off massively in the future. 
Via InvestorPlace
News headline image
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today